このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Innate Pharma 将来の成長

Future 基準チェック /26

Innate Pharma利益と収益がそれぞれ年間21.8%と22.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に1.1% 83.2%なると予測されています。

主要情報

21.8%

収益成長率

83.2%

EPS成長率

Biotechs 収益成長	12.1%
収益成長率	22.7%
将来の株主資本利益率	1.1%
アナリストカバレッジ	Good
最終更新日	31 May 2024

今後の成長に関する最新情報

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 24

Recent updates

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

May 21

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 24

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Dec 21

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Sep 30

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Sep 16

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Jun 09

News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

Mar 30

Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Dec 18

Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Sep 27

Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Aug 04

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

May 12

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Apr 13

Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Mar 26

Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

Nov 11

Revenue Downgrade: Here's What Analysts Forecast For Innate Pharma S.A. (EPA:IPH)

May 13

Is Innate Pharma (EPA:IPH) Using Debt Sensibly?

May 04

A Look At Innate Pharma's (EPA:IPH) Share Price Returns

Feb 26

業績と収益の成長予測

ENXTPA:IPH - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	113	-11	73	174	6
12/31/2025	70	-26	43	133	6
12/31/2024	51	-24	2	27	6
12/31/2023	62	-8	-35	-33	N/A
9/30/2023	57	-35	-34	-32	N/A
6/30/2023	52	-63	-33	-32	N/A
3/31/2023	55	-60	-27	-25	N/A
12/31/2022	58	-58	-20	-19	N/A
9/30/2022	57	-40	-24	-23	N/A
6/30/2022	57	-22	-28	-26	N/A
3/31/2022	41	-34	-44	-42	N/A
12/31/2021	25	-45	-60	-58	N/A
6/30/2021	46	-8	-27	-25	N/A
3/31/2021	58	-4	-45	-38	N/A
12/31/2020	70	-1	-63	-52	N/A
9/30/2020	67	-54	-78	-67	N/A
6/30/2020	63	-44	-93	-83	N/A
3/31/2020	75	-33	-62	-24	N/A
12/31/2019	85	8	-30	35	N/A
9/30/2019	108	5	-17	48	N/A
6/30/2019	130	31	-4	61	N/A
3/31/2019	112	17	-19	14	N/A
12/31/2018	94	3	-34	-33	N/A
9/30/2018	70	-19	-49	-46	N/A
6/30/2018	46	-40	-64	-59	N/A
3/31/2018	45	-44	-59	-53	N/A
12/31/2017	44	-48	-54	-48	N/A
9/30/2017	55	-28	N/A	-43	N/A
6/30/2017	66	-8	N/A	-38	N/A
3/31/2017	66	3	N/A	-37	N/A
12/31/2016	66	13	N/A	-37	N/A
9/30/2016	53	5	N/A	-33	N/A
6/30/2016	41	-2	N/A	-29	N/A
3/31/2016	33	-4	N/A	86	N/A
12/31/2015	25	-7	N/A	202	N/A
9/30/2015	17	-13	N/A	200	N/A
6/30/2015	8	-19	N/A	199	N/A
3/31/2015	8	-19	N/A	91	N/A
12/31/2014	8	-20	N/A	-18	N/A
9/30/2014	11	-15	N/A	-15	N/A
6/30/2014	14	-10	N/A	-12	N/A
3/31/2014	15	-6	N/A	-11	N/A
12/31/2013	17	-3	N/A	-11	N/A
9/30/2013	15	-3	N/A	-12	N/A
6/30/2013	14	-4	N/A	-12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IPH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IPH今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IPH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IPHの収益 ( 22.7% ) French市場 ( 5.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: IPHの収益 ( 22.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IPHの自己資本利益率は、3年後には低くなると予測されています ( 1.1 %)。

Innate Pharma 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Consensus estimates of losses per share improve by 14%

Consensus EPS estimates increase from loss to €0.21 profit

Forecast to breakeven in 2026

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Consensus revenue estimates increase by 13%

Recent updates

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

New minor risk - Profitability

No longer forecast to breakeven

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Consensus estimates of losses per share improve by 14%

Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Consensus EPS estimates increase from loss to €0.21 profit

Forecast to breakeven in 2026

Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

New minor risk - Share price stability

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher

Consensus revenue estimates increase by 13%

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Consensus revenue estimates fall by 18%

First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022)

Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Consensus revenue estimates decrease by 40%, EPS upgraded

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?

Price target increased by 8.3% to €6.37

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts

No longer forecast to breakeven

Consensus revenue estimates increase by 340%

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic

Consensus revenue estimates increase by 11%

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Price target decreased to €6.18

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Consensus estimates of losses per share improve by 41%

First half 2022 earnings: EPS and revenues exceed analyst expectations

Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year

Consensus revenue estimates fall by 11%

Price target decreased to €7.48

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Consensus EPS estimates have been downgraded.

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Consensus forecasts updated

Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts

Consensus forecasts updated

Consensus forecasts updated

Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?

Price target increased to €7.77

First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020)